Ophthalmic Devices Market

The global Ophthalmic Devices Market is valued at USD 65.5 Billion in 2023 and is projected to reach a value of USD 100.27 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 4.85% between 2024 and 2032.

Key highlights of Ophthalmic Devices Market

• North America dominated the market in 2023, obtaining the largest revenue share of 41.5%
• The Asia Pacific will witness remarkable growth during the forecast period
• In 2023, the Vision Care segment dominated the Ophthalmic Devices market with 62.2% market share
• The Hospitals segment continued to assert its dominance by end-users, capturing the largest market share of 78.5% in 2023
• The increasing prevalence of age-related eye disorders like cataracts and macular degeneration, alongside a growing global geriatric population, fuels the Ophthalmic Devices market

Ophthalmic Devices Market: Regional Overview

North America Dominated Sales with a 41.5% share in 2023. The Ophthalmic Devices market growth in North America is driven by a large older population and the escalating prevalence of chronic eye conditions stemming from high stress and unhealthy lifestyles, ultimately leading to diabetic retinopathy. For instance, in 2023, an estimated 9.6 million people in the United States were living with diabetic retinopathy (D.R.), with 1.84 million of them living with vision-threatening D.R. The adoption of new reimbursement models for ophthalmologic treatments and a stringent regulatory framework aimed at patient safety are anticipated to stimulate product demand in the region further. A high disposable income, increasing awareness, a growing geriatric population, and the rising incidence of eye diseases, coupled with the introduction of newer products and devices, further fuel the market for Ophthalmic Devices.

The intensified focus of industry players on innovation and product launches fuels the market's trajectory. For instance, in March 2022, Alcon's introduction of the Clareon family of intraocular lenses (IOLs) in the United States exemplifies this trend, offering consistent visual outcomes and exceptional clarity through advanced IOL material. Furthermore, recent regulatory approvals such as Lumenis Ltd.'s De Novo authorization for their intense pulsed light device to address dry eye disease and WaveFront Dynamics Inc. announced the WaveDyn vision Analyzer's commercial launch in March 2023. These kinds of programs aid in raising awareness of eye conditions and the accessibility of diagnostic tools, further underscoring the region's potential for market expansion and innovation.

U.S. Ophthalmic Devices Market Overview

The US Ophthalmic Devices market, valued at USD 22.3 Billion in 2023 to USD 32.85 Billion in 2032, is anticipated to grow at a CAGR of 4.4% from 2024 to 2032. The US has a strong healthcare system with top academic institutions and research facilities that encourages advancements in ophthalmic technology, such as minimally invasive surgical methods, sophisticated diagnostics, and tailored treatment strategies. Innovative environment and significant healthcare spending is expected to reach USD 6.8 trillion by 2030 and drive investment in specialist therapies and eye care equipment further aiding the market growth. However, the COVID-19 pandemic significantly impacted the U.S. Ophthalmic Devices market, with delayed consultations and restricted import/export affecting device availability. Neovascular Age-Related Macular Degeneration (AMD) eyes experienced vision loss due to postponed therapy, highlighting the pandemic's consequences on eye care. For instance, Age-related macular degeneration is expected to affect 5.4 million Americans by 2050, according to the National Eye Institute, which highlights the rising need for ophthalmic equipment.

The global Ophthalmic Devices market can be categorized as Product, End User and Region.

Ophthalmic Devices Market: Product Overview

In 2023, Vision Care generated a significant revenue of 62.2%. The Product segment is divided into Diagnostic and Monitoring, Surgical, Accessories, and Vision Care. The vision care segment covers a broad spectrum of products and services targeting various visual impairments and promoting eye health. Vision Care includes prescription eyeglasses, contact lenses, and vision correction surgeries like LASIK and PRK. Its strong performance sustained demand for solutions enhancing visual acuity and quality of life across all age groups. A shift from traditional eyeglasses to contact lenses is driven by players' increased focus on launching new contact lens varieties. For instance, according to the CDC, approximately 45 million Americans were using contact lenses, indicative of a rising trend contributing to the vision care segment's expansion.

Ophthalmic Devices Market: End User Overview

The Hospitals & Eye Clinics segment held a significant market share of 78.5% in 2023. The End User segment covers Hospitals & Eye Clinics, Academic & Research Laboratory and Other sectors. The hospitals & eye clinics segment emerged as the largest in 2023, driven by the expanding adoption of ophthalmic devices in hospitals and the provision of cost-effective treatments in clinics. The surge in mergers and acquisitions between ophthalmic clinics and hospitals is anticipated to drive demand for new installations in the upcoming years. For instance, in June 2023, Eye-Q announced the installation of an advanced, customized LASIK equipment at their eye care center in Rewari, India revolutionizing laser vision correction and enhancing patient treatment. Furthermore, establishing separate diagnostic departments within eye clinics amplifies the demand for ophthalmic devices. Additionally, the proliferation of eye clinics offering affordable treatment options is projected to fuel market growth.

Key Trends

• Innovative diagnostic technologies and minimally invasive surgical techniques (MIS) aid the market growth. Both patients and medical practitioners favor surgical methods characterized by fewer incisions, reduced tissue damage, and quicker recovery periods. Advanced diagnostic tools such as optical coherence tomography and ultrasound bio microscopy play a pivotal role in enabling accurate diagnosis and treatment planning through their ability to provide detailed visualizations of eye structures.
• Telemedicine enables patients to consult with ophthalmologists remotely, reducing the need for personal visits, especially in remote or underserved areas. By tracking patients' eye health over time through remote monitoring, medical personnel may ensure prompt interventions and individualized care.
• Integrated systems combine multiple operations into a single platform, including therapy, diagnosis and imaging. These technologies offer complete solutions for ophthalmic practitioners, which optimize workflows, boost productivity, and improve patient care.

Premium Insights

According to the WHO, approximately 2.2 billion people worldwide suffer from distance or near vision impairment, underscoring the need for ophthalmic devices to treat such disorders and correct refractive errors. Phoropters and retinoscopes are highly favored for these purposes. Major key players are focused on introducing advanced ophthalmic diagnosis and treatment devices to meet the demand for eye care treatment. Technological advancements, such as minimally invasive surgical (MIS) techniques and advanced diagnostic tools like optical coherence tomography (OCT), drive demand for innovative ophthalmic devices. Additionally, adopting telemedicine and remote monitoring solutions, particularly amid the COVID-19 pandemic, enhances accessibility and efficiency in eye care delivery.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

The Ophthalmic Devices market is driven by the increasing incidence of eye diseases, including glaucoma, cataracts, and macular degeneration

The aging population is more prone to age-related eye conditions. For instance, the World Health Organization projects that by 2030, 1 in 6 individuals will be 60 years of age or older worldwide, and there will be 2.1 billion people in this age group by 2050. It is also predicted that by 2050, there would be 3 times as many people 80 years of age or older—that is, 426 million people. Additionally, lifestyle factors like high stress, prolonged screen time, and unhealthy habits contribute to the rise in eye disorders. This increase in eye disorders drives the demand for advanced diagnostic tools, such as cataract, optical coherence tomography (OCT), and fundus photography, as well as treatments like laser surgeries and intraocular injections, thereby propelling growth in the Ophthalmic Devices market. For instance, WHO reports cataracts as the leading cause of blindness globally, with nearly 51% of all blindness cases attributed to this condition.

Lower adoption rates of advanced ophthalmic devices like phacoemulsification systems and premium IOLs, creating an opportunity for manufacturers in emerging regions

Factors such as cost constraints and limited access to specialized healthcare facilities present an opportunity for manufacturers to develop cost-effective solutions tailored to the specific needs of these regions. Manufacturers can tap into new markets by offering affordable yet high-quality devices and IOLs and drive growth in areas with untapped potential.

A significant challenge facing the Ophthalmic Devices market is the shortage of skilled professionals, particularly in emerging regions

The procedures like cataract surgeries and retinal treatments, as well as the appropriate use and maintenance of ophthalmic devices requires ophthalmologists, optometrists, and technicians. The adoption of advanced ophthalmic technologies and methods needs more trained/skilled professionals, limiting market growth potential. Investing in coaching and training programs is necessary to address this and build a team of professionals with the necessary skills to efficiently use cutting-edge ophthalmic technologies.

Competitive Landscape

The competitive landscape of the Ophthalmic Devices market is highly competitive, featuring diverse global players and emerging firms from various regions and specialties. Key players such as Bausch Health Companies, Inc., Alcon, Johnson & Johnson, and EssilorLuxottica, alongside prominent innovators like Carl Zeiss Meditec AG, Glaukos Corporation, and Topcon Corporation, drive market dynamics through innovation, partnerships, and technological advancements. The market's vitality is increased by strategic acquisitions and partnerships between established companies and startups. Key players continue to provide safe and effective ophthalmic solutions while navigating the ever-changing healthcare landscape. These factors include regulatory compliance, product quality, and customer service. Sustained growth and leadership in this competitive field require ongoing innovation, market expansion strategies, and a focus on improving patient outcomes.

The key players in the global Ophthalmic Devices market include - EssilorLuxottica, Canon Inc., Glaukos Corporation, Nidek Co., Ltd., Topcon Corporation, Ziemer Ophthalmic Systems, Staar Surgical,Bausch Health Companies, Inc., Alcon, Carl Zeiss Meditec AG, Johnson & Johnson, Hoya Corporation, The Cooper Companies, Inc., Haag-Streit, Quantel Medical, Coburn Technologies, Inc., FCI Ophthalmics, Matronix India Corporation, HEINE Optotechnik, Visionix, Neo Vision, Clear Lab, BVI, DORC, CORZA Medical, Appasamy Associates, Ophtec BV, Lumenis, and Intuvision Labs. among others.

Recent Market Developments

• Bausch + Lomb Corporation introduced INFUSE Multifocal silicone hydrogel daily disposable contact lenses in the US in June 2023. These innovative lenses keep patients' eyes comfortable and free of dryness.
• Bausch + Lomb introduced the TotalVisc viscoelastic system and the StableVisc cohesive ophthalmic viscosurgical device in April 2023. These solutions provide eye surgeons with new choices for dual-action protection during cataract surgery, which assisted in growing the company's product line.
• In August 2022, The U.S. Food and Drug Administration (FDA) granted Glaukos Corporation 510(k) clearance for the iStent Infinite. This trabecular micro-bypass device is designed to lower excessive intraocular pressure (IOP) in patients whose primary open-angle glaucoma has not responded to previous medication or surgical therapy. It can be used as a stand-alone surgery.
• In July 2022, AbbVie and iSTAR Medical S.A. formed a strategic collaboration to further the development and marketing of iSTAR Medical's MINIject device. This minimally invasive glaucoma surgery (MIGS) device is for glaucoma patients.
• In February 2023, ZEISS Medical Technology and Boehringer Ingelheim announced a long-term strategic partnership to develop predictive analytics for early eye disease identification and to keep patients with severe eye disorders from losing their eyesight. Together, their cutting-edge knowledge in ophthalmological technology, data analytics, algorithms, and therapy development will enable early diagnosis and treatment of retinal illnesses, preventing irreversible vision loss.
• In October 2023, A premier worldwide eye health firm, Bausch + Lomb Corporation, announced the introduction of the enVista Aspire monofocal and toric intraocular lenses (IOLs) with Intermediate Optimized (I.O.) optics in the U.S. market. enVista Aspire addresses patients' vision needs in the contemporary, digital world by fusing cutting-edge optics—engineered for a more comprehensive depth of focus—with the well-proven advantages of the enVista platform.
• In March 2022, Alcon introduced The Clareon line of intraocular lenses (IOLs) and made them available for purchase in the United States. These lenses are known for their remarkable clarity and ability to produce consistent visual results.